Considerable numbers of proteins, for example eye lens crystalline, become abnormally insoluble in aged tissues. Because an aggregated insoluble form of crystalline has more racemized aspartate (D-Asp) than its soluble form in cataract lens of elderly patients, it is very likely that the racemization may precede the aggregation (Masters et al. 1978 ; Groenen et al. 1990 ). In Alzheimer's disease, Shapira and colleagues investigated the racemization of amyloid core protein, myelin basic protein (MBP), and other human proteins, demonstrating that Received July 18, 1994; revision accepted for publication September 5, 1994. 251 4.57% ± 1.24 (n = 4) of aspartate in amyloid core protein was D-Asp compared to 7.46%±O.09 (n = 6) in human MB P or 1.99%±O.24 (n=3) in human hair (Shapira et al. 1988) . Amyloid core protein is less racemized than MBP, but apparently more racemized than other proteins included in hair, muscle, and tendon (Shapira et al. 1988 ). Amyloid /3 protein (Af), composed of 39 to 43 amino acids, is produced from a large receptor-like transmembrane precursor termed amyloid precursor protein (APP). A/3 is derived from the region spanning from the C-terminal of the extracellular domain to the N-terminal of the transmembrane domain of the APP molecule (Kang et al. 1987) . Although the mechanism for the generation of A/3 is still undefined, several lines of evidence suggest that its production is not a pathological but a physiological phenomenon. In fact, A/3 is constitutively released from cultured cells ; Shoji et al. 1992 ). In addition, the cerebrospinal fluids of normal individuals contain a comparable level of A/3 to those of patients with Alzheimer's disease Shoji et al. 1992 ). On the other hand, several investigations using synthetic peptides have demonstrated that A/3 shows a tendency for self aggregation (Barrow et al. 1992 ; Burdick et al. 1992; Fraser et al. 1992; ) and that aggregated A/3 is neurotoxic (Pike et al. 1993 ). The aggregation of AR is concentrationdependent (Burdick et al. 1992) , and requires a long time at a physiological concentration, although it rapidly aggregates at an experimental high concentration (Jarrett and Lansbury 1993). To date, several investigations suggest that the production of A/3 is not abnormally increased in Alzheimer's disease except some cases of familial Alzheimer's disease with a point mutation of APP (Citron et al. 1992; Cai et al. 1993) . Therefore other factors modifying the aggregation property of A/3 may play a pivotal role in the accelerated aggregation in Alzheimer's disease. Several factors such as apolipoprotein E4 (Corder et al. 1993 ), a mutation in A/3 (Wisniewski et al. 1991) , the racemization of AR (Shapira et al. 1988 ), or the oxidation of A/3 (Dyrks et al. 1992) , might be necessary for the accelerated aggregation found in Alzheimer's disease.
In the present study, we focused in the role of racemization on the pathological aggregation of A/3 in Alzheimer's disease. Because A/3 extracted from amyloid cores of neuritic plaques has been significantly isomerized and/or racemized at its Asp residues (Roher et al. 1993 ), we addressed the biological function of A/3 racemization by using synthetic All-40 with D-Asp. Three synthetic peptides, i.e., normal A/31-40, [D-Asp7] A/31-40 and [D-Asp23] AR 1-40, were synthesized and compared for their aggregation properties by means of spectrofluorometry and electron microscopy. We showed here that the racemization of Asp residues affects the aggregation properties of A/3. Regardless of the mechanism of racemization, this posttranslational modification of aspartyl or asparaginyl residue may change the properties of proteins, i.e., the solubility, the conformation, and the function of proteins. The significance of racemization on A/3 aggregation was further discussed based on immunohistochemistry by newly prepared anti-racemized A/3 antisera.
MATERIALS AND METHODS Identification of D-amino acids
Brain cortices were homogenized in TS buffer (50 mM Tris-HC1, pH 7.6, 150 mM NaCI) and spun at 100,000 x g for 60 min at 4°C. The resultant supernatant was taken as the soluble fraction and the pellet was washed with 10% SDS in TS buffer. The final pellet was taken and referred to as the insoluble fraction. The final pellet proved to contain A/3 but not neurofibrillary tangles based on immunoblotting with several antibodies against PHF or amyloid protein. Furthermore samples were put onto slide glasses coated with bovine serum albumin and examined for their immunohistochemistry.
Each sample was hydrolyzed in 6 N HC1 at 105°C for 20 hr followed by the determination of racemized amino acids. Dry-up mixtures were coupled with FLEC (+-1-(9-fluorenyl ethyl chloroformate); Fluka, Switzerland) and applied onto reversed-phase HPLC with Supersher C18 column (Merck, Darmstadt, Germany).
Synthesis of peptides
Fmoc amino acids were purchased from Applied Biosystems Inc., and Fmoc-D-Asp (OtBu)-OH was obtained from Bachem Feinchemikalien AG (Switzerland). Three A/31-40 peptides were synthesized by solid-phase methods using a model 431A peptide synthesizer (Applied Biosystems Inc., Tokyo) and purified by reversed-phase HPLC using a cosmosil 5C4-300AR column (Nakarai tesque., Kyoto) (Mori et al. 1992 
Aggregation studies
Aggregation studies were performed according to the method as described (LeVine 1993). The peptides were incubated at room temperature at a concentration of 2001cg/ml in 0.1 M sodium phosphate buffer (pH 7.4). Ten j l of the peptide solution were added in 1 ml of 31aM ThT (Aldrich), 50 mM sodium phosphate buffer (pH 6.0) and mixed by vortex mixing. The fluorescence of the mixture was immediately measured at A ex = 450 nm, 5 nm bandpass; 2. em = 482 nm,10 nm bandpass, using a JASCO FP-770 spectrofluorometer (JASCO; Hachioji).
Electron microscopy
The aggregated peptides in solutions were adsorbed onto 200-mesh formvarcoated copper grids and negative-stained with 2% uranyl acetate. The specimens were viewed for fibrils with a JEM-100CX electron microscope (JEOL, Akishima) at 80 kV.
Immunohistochemistry
For immunostaining, 5 u m paraffin sections from AD brain cortices were treated with xylene, alcohol and hydrated. After blocking with 20% goat serum in TS buffer (50 mM Tris-HC1, pH 7.6, 150 mM NaCI), the sections were incubated with rabbit polyclonal antisera (1: 400) against [D-Asp', D-Asp23] All-35 overnight at 4°C (Endoh et al. 1993) . The sections were then incubated with biotynated anti-rabbit IgG as the second antibody followed by avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The peroxidase activity was developed with 0.05% 3, 3'-diaminobenzidine and 0.01% H202 in 50 muM Tris-HC1 (pH 7.6) for 5 min.
RESULTS

Identification of racemized amino acids in the soluble fraction and insoluble fraction prepared from AD brains
The soluble fraction was obtained as the supernatant fraction of AD brain homogenate as described in materials and methods. We detected D-Asp (4.54%), D-Glu (2.25%), D-Ala (1.07%) and D-Lys (4.76%) in the soluble fraction of AD brain cortices (Table 1) . We next investigated the insoluble fraction that essentially composed of amyloid protein and lipofuscin and compared them to those in the soluble fraction. In the insoluble fraction, we detected higher ratio of D-Asp (7.31%), D-Glu (2.15%), D-Ala (1.52%), and D-Lys (16.8%) compared to those in the soluble fraction as shown in Table 1 . Especially D-Lys was four times increased among racemized amino acids. We also detected D-Arg (5.41%), D-Val (1.68%), D-Ile (3.79%) and D-Tyr (4.81%) which were not detected in the soluble fraction of AD brain cortices. In this study, Asp and Lys were both highly racemized (Table 1) , which was in good agreement with some of the previous study (Roper et al. 1993) .
To clarify further the significance of racemization in the formation of senile plaques, we prepared the specific antibodies which recognize All-35 with D-Asp or A/31-42, respectively. As shown in Figs. lB and 1D, senile plaques and blood vessels were positively stained with anti-racemized A/31-35 antibody, demonstrating histologically the incorporation of racemized A/3 in amyloid deposits of AD brains. Since anti-All-42 antibody could recognize A/31-42/43 species rather than A131-40 species and stained wider populations of senile plaques (Fig. lA and 1C ) than anti-racemized A/3 antibody did, the incorporation of A/31-42/43 may occur in plaque formation at the earlier stage than the racemization of A/3.
Effect of racemized Asp in A/3 on its aggregation property and protein conformation
Three synthetic A/31-40 peptides were solubilized to a concentration of 200 jug/ml in 0.1 M sodium phosphate buffer (pH 7.4) and investigated for their aggregation properties. The peptide solutions were incubated at room temperature, and an aliquot was mixed with ThT followed by the measurement of its aggregation. On day 7, normal A/3 peptide started to aggregate (Fig. 2) when the neurotoxicity was generally reported to be induced (Pike et al. 1993 ). In contrast to normal A/3, [D-Asp7] AS1-40 showed an enhanced aggregation. [D-Asp23] AS 1-40, however, showed slightly retarded increase at the initial stage but much higher increase at the final stage (Fig. 2) . The present results on AS1-40 were somewhat inconsistent with our previous report on AS1-35 with respect to the starting point for peptide aggregation (Tomiyama et al. 1994 ). We speculate, however, that the carboxyl terminal portion (the five amino acids-stretch of AS36-40) may change the way of the involvement of D-Asp7 or D-Asp23 in the aggregation process of A/31-35 or A/31-40. This idea may also be supported by the current hypothesis proposed by Jarrett and Lansbury (1993) that the long-tail form of A/3 (A/31-42/43) plays a seeding role while the short-tail form of A/3 (AS1-40) does an elongation roles as described in the discussion.
Electron microscopy
To confirm the structural changes of A/3 aggregation, we further investigated the aggregation properties of All-40 peptides by electron microscopy. Corre- sponding to the increase in ThT assay and the appearance of a smear in SDS-PAGE (data not shown), fibril formation was observed in three peptide solutions. On day 1 and day 7, no fibrils were observed in any of the peptide solutions. On (Fig. 3) . The fibrils then grew larger during the incubation and finally all peptides showed fibril formation.
DISCUSSION
Neuronal degeneration is the most important pathological feature in Alzheimer's disease. Although the molecular basis of neuronal cell death is still unclear, amyloid deposition is believed to be involved in this process. Several reports have revealed that exogenous AR causes neuronal degeneration in primary cultured neurons (Yankner et [G1u22]AR1-28 peptide solution. Dyrks et al. (1993) have shown that the aggregation of A/3 and the C-terminal amyloidogenic APP fragments depend on oxidation of His, Tyr and Met residues, and that the addition of radical scavengers prevents the aggregation process induced by metal-catalyzed oxidation systems (Dyrks et al. 1992) . The report that the iron homeostasis is disrupted in Alzheimer's disease brains (Kawamata et al. 1993 ) may also supports the involvement of metal-catalyzed radical reactions in the aggregation process of AR (Dyrks et al. 1992) . In addition to these findings, racemization was another modification of A/3, which modulate the aggreation of A/3 (Tomiyama et al. 1994 ). Indeed, Shapira et al. (1988) have reported that their amyloid preparations from Alzheimer's disease brains contain approximately 5% D-Asp and 2% D-Ser. Another example for the presence of pathological racemization was provided by Fisher et al. (1992) who found that proteins of neurofibrillary tangles from Alzheimer's disease brains were also racemized. Recently, Roher et al. (1993) have extensively examined the structure of A/3 extracted from the amyloid cores of neuritic plaques and have identified altered Asp residues: Asp residues at positions 1 and 7 represent as a mixture of normal Asp and iso-Asp isomers in both the D-and L-configurations.
At these positions, L-iso-Asp predominates while D-iso-Asp, L-Asp, and D-Asp represent in lesser amounts.
On the basis of these observations, we synthesized A/3 peptide in which D-Asp was substituted for L-Asp residues and compared their aggregation properties. Here, we show that the racemization of Asp residues affects the polymerization property of these Afs. Racemization at position 7 accelerated the A/3 peptide aggregation. These results suggest that the effect of racemization is site-specific in A/3 structure. Therefore, the aggregation of peptides could be enhanced or suppressed due to the structural alterations caused by the incorporation of site-specific D-Asp residue.
Taken together with the recent finding that brain amyloid is in a dynamic equilibrium between the soluble and insoluble forms (Maggio et al. 1992) , the racemization of Asp7 may play a significant role in the increase of AR deposition in AD brains by shifting an equilibrium of A/3 from soluble form to insoluble form. The comparative study of immunohistochemistry in the brain sections with anti-racemized A/3 and anti-All-42 antisera showed that A/31-42/43 species was dominant among senile plaques (Fig. l) and strongly indicated that racemization occurred later than A/31-42/43 deposition. Our present finding was compatible with the recent study that A/31-42/43 species was dominantly found in senile plaques with captured-antibodies against two carboxyl termini (-40 and -42/43) of A/3 (Iwatsubo et al. 1994) .
It is known that racemization and isomerization of proteins occur spontaneously at physiological temperature and pH, without enzymatic reactions (Geiger and Clarke 1987; Stephenson and Clarke 1989) . These stereoconversions are more frequently found in long-lived proteins, and altered proteins with these modofications are increased with aging (Bada 1984; Masters 1983 ). This may well explain why neuropathogenesis of AD occurs in an age-dependent manner. In normal individuals, yet undefined repair/degradation systems for racemized proteins are presumably at work in central nervous system. Carboxyl methyltransferase is a candidate as a specific repair enzyme in this system (Johnson et al. 1987 Lowenson and Clarke 1992) in addition to the well-established another repairing system by ubiquitin (Mori et al. 1987) . This enzyme has a specificity for L-iso-Asp and D-Asp but not L-Asp or D-iso-Asp, and it transfers methyl groups to altered amino acids in peptides (Johnson et al. 1987; Lowenson and Clarke 1992) . Because carboxyl methyltransferase was actually expressed in an up-regulated manner at both mRNA and protein levels in Alzheimer's disease brains (manuscript in preparation), this enzyme may not overcome the massive accumulation of its substrates in Alzheimer's disease. In conclusion, we have shown, using synthetic full-sized A/3 aggregation properties of A/3 are influenced by racemization of depending on their position. Racemization may occur after the formation and alter the equilibrium shift of AQ between soluble forms in Alzheimer's disease.
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